Departments, Centers, & Programs:
Center for Genomic Medicine
185 Cambridge Street
Simches Research Ctr
Boston, MA 02114
- Residency, Brigham and Women's Hospital
- Fellowship, Massachusetts General Hospital
American Board Certifications
- Neurology, American Board of Psychiatry and Neurology
Accepted Insurance Plans
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
The Anderson laboratory espouses the mission of the MGH Center for Genomic Medicine as it applies to ischemic stroke and intracerebral hemorrhage (ICH). We employ translational and computational techniques to understand how genetic associations can teach us about the pathogenic mechanisms of stroke, and how we can apply genetic associations to guide therapeutic and diagnostic approaches at the bedside. Members of the Anderson lab use population genetics approaches to the study of cerebrovascular disease, with special emphasis on pathway-based and translational genomic techniques that clarify the causal biological mechanisms through which associated genetic variants exert their influence on disease risk and outcome.
Programs within the lab include: 1) Leveraging genetic tools to understand how risk factors influence the development of cerebrovascular disease, 2) Determining the causal mechanisms through which common and rare genetic variants lead to ICH, and 3) Developing precision genomic medicine tools for stratification of genetic risk in individuals at risk for ischemic stroke. Because genetic analyses require both clinical characteristics as well as genotypic information, members of the lab cultivate expertise in multiple clinical, imaging, and computational domains. Fellows, coordinators, and students in the lab devote their efforts to projects across these disciplines, including clinical contact with stroke survivors for determination of outcomes, ascertainment of qualitative and quantitative imaging phenotypes for genetic and epidemiologic studies, and application of advanced bioinformatic tools for interpretation and analysis of genetic and genomic data. All of these enterprises serve the common goal of improving our understanding of cerebrovascular disease, so that we may develop new approaches to reduce the burden of stroke in the patients we serve.